Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- Meta CEO Mark Zuckerberg Says In Internal Town Hall That Ai Agent Development Over The Last Four Months Hasn't 'accelerated In The Way We Expected' - Reuters
RBC Capital on Acadia Pharmaceuticals (ACAD): 'We see a -1-2% stock move off the Nuplazid slight miss for 1Q23'
May 8, 2023 4:39 PM EDTRBC Capital analyst Gregory Renza reiterated an Outperform rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "Potential stock impact & bottom line: We see a -1-2% stock move off the Nuplazid slight miss for 1Q23, reiterated FY23 revenue guidance, offset by optimism around Daybue launch... More
